Platelets play an important role in cardiovascular thrombosis as well as in many other
pathological conditions such as inflammation, atherosclerosis and cancer. While multi-target strategies
to treat complex diseases are gaining considerable attention, current development of antiplatelet
therapies is mostly oriented towards several single targets, arising from our present understanding of
the regulation of platelet activation. Limited efforts to develop multi-target agents or multidrug
therapies are mostly due to a lack of a systematic basis to define target combinations with synergistic effects. Here we
discuss the perspective to use high content phenotypic screening of in vitro models as a potential source for inference of
synergetic multi-target strategies to control platelet activation.
Keywords: Antiplatelet therapies, CASP3, COX1, high content screening, KLF5, multi-target therapies, NPC1, PKM,
polypharmacology, platelets, SENP6, TNFSF10, SENP.
Rights & PermissionsPrintExport